Vascular effects of improving metabolic control with metformin or rosiglitazone in type 2 diabetes

Diabetes Care

Volumn 27, Issue 6, 2004, Pages 1349-1357

  Natali, Andrea ^a,e   Baldeweg, Stephanie ^b   Toschi, Elena ^a   Capaldo, Brunella ^c   Barbaro, Daniele ^d   Gastaldelli, Amalia ^a   Yudkin, John S ^b   Ferrannini, Ele ^a  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^d Livorno Hospital   (Italy)

^e Department of Internal Medicine ^*  (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FATTY ACID; FIBRIC ACID DERIVATIVE; GLUCOSE; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; METFORMIN; NITRIC OXIDE SYNTHASE; NITROPRUSSIDE SODIUM; PLACEBO; ROSIGLITAZONE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; AMBULATORY MONITORING; ARTICLE; BLOOD PRESSURE MONITORING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; ENDOTHELIUM CELL; FEMALE; FOREARM BLOOD FLOW; HUMAN; INSULIN BLOOD LEVEL; INSULIN SENSITIVITY; LEAN BODY WEIGHT; MAJOR CLINICAL STUDY; MALE; METABOLIC REGULATION; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; VASCULAR DISEASE; VASODILATATION;

ACETYLCHOLINE; BLOOD FLOW VELOCITY; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FEMALE; FOREARM; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MIDDLE AGED; NITROPRUSSIDE; THIAZOLIDINEDIONES;

EID: 2542424151     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.27.6.1349     Document Type: Article

References (48)

1. Howard B, Rodriguez B, Bennet P, Harris M, Hamman R, Kuller L, Pearson T, Wylie-Roset J: Prevention Conference VI: diabetes and cardiovascular disease: Writing Group I: epidemiology. Circulation 105:e132-e137, 2002
2. Natali A, Vichi S, Landi P, Severi S, L'Abbate A, Ferrannini E: Coronary atherosclerosis in type II diabetes: angiographic findings and clinical outcome. Diabetologia 43:632-641, 2000
3. Vane JR, Anggard EE, Botting RM: Regulatory functions of the vascular endothelium. N Engl J Med 323:27-36, 1990
4. Quyyumi AA: Endothelial function in health and disease: new insights into the genesis of cardiovascular disease. Am J Med 105:32S-39S, 1998
5. Enderle M, Benda N, Schmuelling R, Haering H, Pfohl M: Preserved endothelial function in IDDM patients, but not in NIDDM patients, compared with healthy subjects. Diabetes Care 21:271-277, 1998
6. Balletshofer B, Ritting K, Enderle M, Volk A, Maerker E, Jacob S, Matthaei S, Rett K, Haring H: Endothelial dysfunction is detectable in young normotensive first-degree relatives of subjects with type 2 diabetes in association with insulin resistance. Circulation 101:1780-1784, 2000
7. Williams S: Impaired nitric oxide-mediated vasodilation in patients with non-insulin-dependent diabetes mellitus. J Am Coll Cardiol 27:567-574, 1996
8. Makimattila S, Liu M-L, Vakkilainen J, Shlenzka A, Lahdenpera S, Syvanne M, Mantysaary M, Summanen P, Bergholm R, Taskinen M-R, Yki-Jarvinen H: Impaired endothelium-dependent vasodilation in type 2 diabetes: relation to LDL size, oxidized LDL, and antioxidants. Diabetes Care 22:973-981, 1999
9. Heitzer T, Krohn K, Albers S, Meinertz T: Tetrahydropterin improves endothelium-dependent vasodilation by increasing nitric oxide activity in patients with type 2 diabetes mellitus. Diabetologia 43:1435-1438, 2000
10. Steinberg HO, Chaker H, Learning R, Johnson A, Brechtel G, Baron A: Obesity insulin resistance is associated with endothelial dysfunction: implication for the syndrome of insulin resistance. J Clin Invest 97:2061-2610, 1996
11. Preik M, Kelm M, Rosen P, Tschope D, Strauer B: Additive effect of coexistent type 2 diabetes and arterial hypertension on endothelial dysfunction in resistance arteries of human forearm vasculature. Angiology 51:545-554, 2000
12. Abe H, Yamada N, Kamata K, Kuwaki T, Shimada M, Osuga J, Shionori F, Yahagy N, Kadowaki T, Tamemoto H, Ishibashi S, Yazaki Y, Makuuki M: Hypertension, hypertriglycemia, and impaired endothelium-dependent vascular relation in mice lacking insulin receptor substrate-1. J Clin Invest 101:1784-1788, 1998
13. Shankar RR, Wu Y, Shen HQ, Zhu JS, Baron AD: Mice with gene disruption of both endothelial and neuronal nitric oxide synthase exhibit insulin resistance. Diabetes 49:684-687, 2000
14. Walker AB, Chattington PD, Buckingam RE, Williams G: The thiazolidinedione rosiglitazone (BRL-49653) lowers blood pressure and protects against impairment of endothelial function in Zucker fatty rats. Diabetes 48:1448-1451, 1999
15. Diep QN, El Mabrouk M, Cohn JS, Endemann D, Amiri F, Virdis A, Neves MF, Schiffrin EL: Structure, endothelial function, cell growth, and inflammation in blood vessels of angiotensin II-infused rats: role of peroxisome proliferator-activated receptor-γ. Circulation 105:2296-2302, 2002
16. Vehkavaara S, Makimattila S, Schlenzka A, Vakkilainen J, Westerbacka J, Yki-Jarvinen: Insulin therapy improves endothelial function in type 2 diabetes. Arterioscler Thromb Vasc Biol 20:545-550, 2000
17. Mather K, Verma S, Anderson T: Improved endothelial function with metformin in type 2 diabetes mellitus. J Am Coll Cardiol 37:1344-1350, 2001
18. Wolfe RR: Radioactive and Stable Isotope Tracers in Biomedicine: Principles and Practice of Kinetic Analysis. New York, Wiley, 1992
19. DeFronzo RA, Tobin JD, Andres R: Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 237:E214-E223, 1979
20. Mari A: Estimation of the rate of appearance in the non-steady state with a two-compartment model. Am J Physiol 263: E400-E415, 1992
21. Inzucchi SE, Maggs DG, Spollett GR, Page SL, Rife FS, Walton V, Shulman GI: Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. N Engl J Med 338:867-872, 1998
22. Dorella M, Giusto M, Da Tos V, Campagnolo M, Palatini P, Rossi G, Ceolotto G, Felice M, Semplicini A, Del Prato S: Improvement of insulin sensitivity by metformin treatment does not lower blood pressure of nonobese insulin-resistant hypertensive patients with normal glucose tolerance. J Clin Endocrinol Metab 81:1568-1574, 1996
23. Prager R, Schernthaner G, Graf H: Effect of metformin on peripheral insulin sensitivity in non insulin dependent diabetes mellitus. Diabetes Metab 12:346-350, 1986
24. DeFronzo RA, Barzilai N, Simonson DC: Mechanism of metformin action in obese and lean noninsulin-dependent diabetic subjects. J Clin Endocrinol Metab 73:1294-1301, 1991
25. Cusi K, Consoli A, DeFronzo RA: Metabolic effects of metformin on glucose and lactate metabolism in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 81:4059-4067, 1996
26. Abbasi F, Carantoni M, Chen YD, Reaven GM: Further evidence for a central role of adipose tissue in the antihyperglycemic effect of metformin. Diabetes Care 21:1301-1305, 1998
27. Hother-Nielsen O, Schmitz O, Andersen PH, Beck-Nielsen H, Pedersen O: Metformin improves peripheral but not hepatic insulin action in obese patients with type II diabetes. Acta Endocrinol (Copenh) 120:257-265, 1989
28. Miyazaki Y, Glass L, Triplitt C, Matsuda M, Cusi K, Mahankali A, Mahankali S, Mandarino LJ, DeFronzo RA: Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in type II diabetic patients. Diabetologia 44:2210-2219, 2001
29. Utriainen T, Malmstrom R, Yki-Jarvinen H: Methodological aspects, dose-response characteristics and causes of interindividual variation in insulin stimulation of limb blood flow in normal subjects. Diabetologia 38:555-564, 1995
30. Trovati M, Masucco P, Mattiello L, Cavalot F, Mularoni E, Hahn A, Anfossi G: Studies on the influence of insulin on cyclic adenosine monophosphate in human vascular smooth muscle cells: dependence on cyclic guanosine monophosphate and modulation of catecholamine effects. Diabetologia 39:1156-1164, 1996
31. Cardillo C, Nambi SS, Kilcoyne CM, Choucair WK, Katz A, Quon MJ, Panza JA: Insulin stimulates both endothelin and nitric oxide activity in the human forearm. Circulation 100:820-825, 1999
32. Zeng G, Nystrom FH, Ravichandran LV, Cong LN, Kirby M, Mostowski H, Quon MJ: Roles for insulin receptor, PI3-kinase, and Akt in insulin-signaling pathways related to production of nitric oxide in human vascular endothelial cells. Circulation 101:1539-1545, 2000
33. Cong LN, Chen H, Li Y, Zhou L, McGibbon MA, Taylor SI, Quon MJ: Physiological role of Akt in insulin-stimulated translocation of GLUT4 in transfected rat adipose cells. Mol Endocrinol 11:1881-1890, 1997
34. Steinberg HO, Tarshoby M, Monestel R, Hook G, Cronin J, Johnson A, Bayazeed B, Baron AD: Elevated circulating free fatty acid levels impair endothelium-dependent vasodilation. J Clin Invest 100:1230-1239, 1997
35. Marx N, Kehrle B, Kohlhammer K, Grub M, Koenig W, Hombach V, Libby P, Plutzky J: PPAR activators as antiinflammatory mediators in human T lymphocytes: implications for atherosclerosis and transplantation-associated arteriosclerosis. Circ Res 90:703-710, 2002
36. Haffner SM, Greenberg AS, Weston WM, Chen H, Williams K, Freed MI: Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 106:679-684, 2002
37. Stuhlinger MC, Abbasi F, Chu JW, Lamendola C, McLaughlin TL, Cooke JP, Reaven GM, Tsao PS: Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor. JAMA 287:1420-1426, 2002
38. Garg U, Hassid A: Nitric oxide-generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J Clin Invest 83:1774-1777, 1989
39. Ikeda H, Takajo Y, Murohara T, Ichiki K, Adachi H, Haramaki N, Katoh A, Imaizumi T: Platelet-derived nitric oxide and coronary risk factors. Hypertension 35:904-907, 2000
40. Bath P, Hassall D, Gladwin A, Palmer R, Martin J: Nitric oxide and prostacyclin: divergence of inhibitory effects on monocyte chemotaxis and adhesion to endothelium in vitro. Arterioscler Thromb Vasc Biol 11:254-260, 1991
41. Suwaidi JA, Hamasaki S, Higano ST, Nishimura RA, Holmes DR Jr, Lerman A: Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation 101:948-954, 2000
42. Perticone F, Ceravolo R, Pujia A, Ventura G, Iacopino S, Scozzafava A, Ferraro A, Chello M, Mastroroberto P, Verdecchia P, Schillaci G: Prognostic significance of endothelial dysfunction in hypertensive patients. Circulation 104:191-196, 2001
43. Heitzer T, Schlinzig T, Krohn K, Meinertz T, Munzel T: Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary, artery disease. Circulation 104:2673-2678, 2001
44. Marx N, Schonbeck U, Lazar MA, Libby P, Plutzky J: Peroxisome proliferator-activated receptor γ activators inhibit gene expression and migration in human vascular smooth muscle cells. Circ Res 83:1097-1103, 1998
45. Law RE, Meehan WP, Xi XP, Graf K, Wuthrich DA, Coats W, Faxon D, Hsueh WA: Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia. J Clin Invest 98:1897-1905, 1996
46. Wakino S, Law RE, Hsueh WA: Vascular protective effects by activation of nuclear receptor PPARγ. J Diabetes Complications 16:46-49, 2002
47. Minamikawa J, Tanaka S, Yamauchi M, Inoue D, Koshiyama H: Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab 83:1818-1820, 1998
48. Koshiyama H, Shimono D, Kuwamura N, Minamikawa J, Nakamura Y: Rapid communication: inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab 86:3452-3456, 2001